The final, formatted version of the article will be published soon.
MINI REVIEW article
Front. Endocrinol.
Sec. Cellular Endocrinology
Volume 15 - 2024 |
doi: 10.3389/fendo.2024.1528248
This article is part of the Research Topic Unraveling Immune Metabolism: Single-Cell & Spatial Transcriptomics Illuminate Disease Dynamics View all 4 articles
Title：Exploring the Role of Metabolic Pathways in TNBC Immunotherapy: Insights from Single-Cell and Spatial Transcriptomics
Provisionally accepted
Shi-liang Chen
1
Yi-Ran Fei
2
Xin-Xian Cai
3*
Cong Wang
1*
Shi-Yuan Tong
4
Zhe- Zhong Zhang
1*
Yan-Xia Huang
1*
Dan-Dan Bian
1*
Yi-bo He
1*
Xiao-Xiao Yang
1*- 1 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine）, Hangzhou, China
- 2 The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China
- 3 School of Medical Technology and lnformation Engineering, Zhejiang Chinese Medical University, Hangzhou, Jiangsu Province, China
- 4 Institutes of Brain Science, Fudan University, Shanghai, Shanghai Municipality, China
The article provides an overview of the current understanding of the interplay between metabolic pathways and immune function in the context of triple-negative breast cancer (TNBC). It highlights recent advancements in single-cell and spatial transcriptomics technologies, which have revolutionized the analysis of tumor heterogeneity and the immune microenvironment in TNBC. The review emphasizes the crucial role of metabolic reprogramming in modulating immune cell function, discussing how specific metabolic pathways, such as glycolysis, lipid metabolism, and amino acid metabolism, can directly impact the activity and phenotypes of various immune cell populations within the TNBC tumor microenvironment. Furthermore, the article explores the implications of these metabolic-immune interactions for the efficacy of immune checkpoint inhibitor (ICI) therapies in TNBC, suggesting that strategies targeting metabolic pathways may enhance the responsiveness to ICI treatments. Finally, the review outlines future directions and the potential for combination therapies that integrate metabolic modulation with immunotherapeutic approaches, offering promising avenues for improving clinical outcomes for TNBC patients.
Keywords: Triple-negative breast cancer, metabolic reprogramming, immune cell function, immune checkpoint inhibitors, Combination therapies, Tumor Microenvironment
Received: 14 Nov 2024; Accepted: 17 Dec 2024.
Copyright: © 2024 Chen, Fei, Cai, Wang, Tong, Zhang, Huang, Bian, He and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xin-Xian Cai, School of Medical Technology and lnformation Engineering, Zhejiang Chinese Medical University, Hangzhou, 310053, Jiangsu Province, China
Cong Wang, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine）, Hangzhou, China
Zhe- Zhong Zhang, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine）, Hangzhou, China
Yan-Xia Huang, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine）, Hangzhou, China
Dan-Dan Bian, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine）, Hangzhou, China
Yi-bo He, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine）, Hangzhou, China
Xiao-Xiao Yang, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine）, Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.